Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anthelminthic Agents01:15

Anthelminthic Agents

49
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
49
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

752
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
752
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

824
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
824
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

1.1K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity against the Human Malaria Parasite <i>Plasmodium falciparum</i> via Polypharmacological Inhibition of <i>Pf</i>Ark1 and Hemozoin Formation.

ACS chemical biology·2026
Same author

Synthesis, Antiparasitic Activity and Substituent Effects of Methyl 5-(Hetero)aryl or Alicyclicaminothieno[2,3-<i>b</i>]pyridine-2-carboxylates.

Molecules (Basel, Switzerland)·2026
Same author

Integrated analysis of humoral and T-cell responses to pneumococcal vaccination in allogeneic hematopoietic stem cell transplant recipients.

Frontiers in medicine·2026
Same author

Insights on genomic profiles of drug resistance and virulence in a cohort of Leishmania infantum isolates from the Mediterranean area.

Parasites & vectors·2025
Same author

Design of 2-Aminobenzothiazole Derivatives Targeting Trypanosomatid PTR1 by a Multidisciplinary Fragment Hybridization Approach.

Journal of medicinal chemistry·2025
Same author

From pan-active to parasite-selective antiparasitic agents: A scaffold hopping approach.

European journal of medicinal chemistry·2025

Related Experiment Video

Updated: Mar 31, 2026

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing &#946;-galactosidase
08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

3.9K

Current and Future Chemotherapy for Chagas Disease.

Luís Gaspar, Carolina B Moraes, Lucio H Freitas-Junior

  • 1Instituto de Investigacao e Inovacao em Saude, Rua Alfredo Allen 208, 4200-135 Porto, Portugal. cordeiro@ibmc.up.pt.

Current Medicinal Chemistry
|October 20, 2015
PubMed
Summary

Chagas disease, a neglected illness, needs new treatments as current options are decades old and ineffective. Research is exploring novel drug discovery for Trypanosoma cruzi to improve patient outcomes.

More Related Videos

Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response
07:59

Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response

Published on: May 31, 2024

2.2K
Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates
13:55

Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates

Published on: January 27, 2019

15.8K

Related Experiment Videos

Last Updated: Mar 31, 2026

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing &#946;-galactosidase
08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

3.9K
Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response
07:59

Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response

Published on: May 31, 2024

2.2K
Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates
13:55

Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates

Published on: January 27, 2019

15.8K

Area of Science:

  • Neglected tropical diseases
  • Infectious diseases
  • Drug discovery and development

Background:

  • Human American trypanosomiasis (Chagas disease) is a prevalent, chronic infectious disease in Latin America with limited treatment options.
  • Existing therapies, introduced 50 years ago, have significant side effects and questionable efficacy in the chronic stage, characterized by cardiomyopathy and megavisceras.
  • Recent clinical trials have shown limited diversity and pipeline fragility, highlighted by the failure of posaconazole and E1224 in Phase 2 trials.

Purpose of the Study:

  • To review historical and current drug discovery efforts for Trypanosoma cruzi.
  • To analyze the present research landscape for Chagas disease therapeutics.
  • To identify opportunities for developing improved and safer treatments for Chagas disease.

Main Methods:

  • Comprehensive review of academic, industry, and organizational research findings over the past 50 years.
  • Analysis of the current drug discovery pipeline for Chagas disease.
  • Evaluation of recent clinical trial outcomes and their implications.

Main Results:

  • Decades of research have yielded limited therapeutic advancements for Chagas disease.
  • The current drug discovery pipeline is fragile, with recent clinical trial failures underscoring the need for novel approaches.
  • Despite setbacks, the research landscape is more promising than ever for developing alternative treatments.

Conclusions:

  • There is a critical need for continuous, high-quality drug discovery and development for Chagas disease.
  • Novel therapeutic strategies are essential to overcome the limitations of existing treatments.
  • The current research environment offers significant potential for delivering effective alternative treatments in the near future.